Prevalence and Risk of Pulmonary Hypertension in Chronic Kidney Disease

Ali Abdul Majid Dyab Allawi¹, Mohammed Hannon Alsodani², Ahmed Mushhin Hardan Alqaisi³

¹FRCP London, Assistant Professor, Department of Internal Medicine, Baghdad College of Medicine
Consultant Nephrologist, Baghdad Teaching Hospital, Baghdad, Iraq

²Consultant Nephrologist, Lecturer at Baghdad College of Medicine, Baghdad, Iraq

³Internist and Specialist, Baghdad Teaching Hospital, Baghdad, Iraq

Abstract: Pulmonary hypertension is common in chronic kidney disease patients treated by hemodialysis (30%). Objectives: The prevalence of Pulmonary hypertension in chronic kidney disease in Baghdad teaching hospital. Patients and methods: Study performed from April 2015 to April 2016, patients with valvular heart disease, pulmonary diseases with abnormal pulmonary function test were excluded, all patients did pulmonary function test before Doppler echo to avoid false positive results, About 80 patients, 40 with chronic kidney disease pre-dialysis 27 male and 13 female, and 40 treated by hemodialysis 22 male and 18 female from dialysis units and medical wards. Results and discussion: Mean age was 51.6 ± 14.2 in predialysis group, and 53.4 ± 12.6 in dialysis group (ranging from 20 to 70 years). Dialysed patients carry increasing risk for having Pulmonary hypertension (OR = 3) compare to predialysis. Anemia increase the risk for development of PH with an OR = 3.42. As the stage of chronic kidney disease increase the incidence of PH increase in which in stage V it reach 15% compare to stage IV 3.75% and lower in the other stages. Patients with age above 50 represent 70.6% of PH patients, so age increase the prevalence of pulmonary hypertension.

Keywords: pulmonary hypertension, chronic kidney disease, predialysis, hemodialysis.

1. Introduction

The prevalence of (PH), defined as Doppler-derived pulmonary artery systolic pressure (PASP)>35 mm Hg, was ~5%. Most cases detected in Olmsted County were related to underlying left ventricular (LV) disorders: PASP was associated with both systemic hypertension and high pulse pressure and with diastolic dysfunction as measured by the E/e’ ratio (early transmitral flow velocity [E] to early mitral annular tissue velocity [e’]) [1]. In this diagnostic category, the prevalence of pulmonary artery hypertension related to background diseases is 7%-12% in systemic sclerosis [2][3], 2%-6% in portal hypertension, and ~30% in congenital heart disease. PH is exceedingly prevalent (15%-20%) in patients with sleep apnea (WHO diagnostic category III)[4].

Various PASP cutoffs have been applied, ranging from 25 to ≥45 mm Hg, and in one study, TRV ≥2.5 m/s was adopted as the major criterion to make the diagnosis of PH [5][6][7]. Hypertension and diabetes mellitus (DM), 2 dominant causes of kidney disease, trigger LV diastolic dysfunction, an alteration found to increase pulmonary venous and arterial pressure. Chronic volume overload, a factor implicated in LV disorders and in the high venous return in patients with CKD, may induce pulmonary venous hypertension by both increasing pulmonary blood flow and adversely affecting LV function [8]. If sustained, vasoconstriction in the lung leads to extensive remodeling of the pulmonary vessels and a steady reduction in vessel compliance, a phenomenon which in and of itself contributes to pulmonary hypertension [9][10]. Well-performed studies show that pulmonary pressure increases with AVF creation [11] and that PH tends to worsen over time in these populations. Accordingly, in HD patients, AVF flow and AVF duration are related independently to the severity of pulmonary hypertension. AVF compression by a sphygmomanometer or surgical AVF closure[12] induces a rapid decrease in mean cardiac output followed by a stable decrease in pulmonary pressure.

PH is higher with HD than PD. Exposure to dialysis membranes, Neutrophil activation Secondary to blood–dialysis membrane contact accompanied by reversible neutrophil sequestration in the lung, a phenomenon that was intensively investigated in the 1980s, contributes to causing or worsening microvascular lung disease in HD patients [13].

The hypothesis that volume overload and LV disorders triggered or exacerbated by kidney disease and repeated exposure to dialysis membranes may cause PH independently of the AVF and other factors is supported by the demonstration that kidney transplantation may revert pulmonary artery pressure to normal in patients ho still have a functioning AVF[14]. Endothelial Dysfunction Endothelial dysfunction is a main trigger of PH in patients with CKD, in whom endothelial dysfunction is prevalent [15]. The impaired capacity of the endothelium to regulate vascular tone in patients with CKD depends on an imbalance between vasoconstrictors (e.g., high levels of endothelin 1) and vasodilators (reduced generation of nitric oxide [NO]) [16]. So, asymmetric dimethyl arginine (ADMA), an endogenous inhibitor of NO synthase that is synthesized widely at lung level and that accumulates in CKD, ADMA is a reasonable uremic toxin potentially implicated in PH in this population [17]. Sleep apnea is a factor of great importance for the high risk of PH in the setting of CKD [18], and a close link between oxygen saturation and PAP has been established in clinical physiology experiments in both healthy persons and patients with chronic obstructive pulmonary disease.

Volume 6 Issue 7, July 2017
www.ijsr.net
Licensed Under Creative Commons Attribution CC BY

Paper ID: ART20175278
DOI: 10.21275/ART20175278 947
Sympathetic activation is the main mechanism whereby hypoxemia increases pulmonary pressure [19]. In this respect, it is interesting to note that patients with sleep-disordered breathing have increased ADMA levels[20]. Furthermore, circulating levels of this NO synthase inhibitor are associated with sympathetic nerve activity (as assessed by measurements in the peroneal nerve) in patients with CKD and with norepinephrine levels in dialysis patients [21, 22].

Severe anemia is an established cardiovascular risk factor in CKD and its impact on the cardiovascular system extends to pulmonary circulation because low hemoglobin levels can contribute to PH by aggravating hypoxia triggered by concomitant conditions [23].

2. Patients and methods

Patient selection: The original study population included 80 patients 50%/40 treated by conservative treatment (control group) & 50%/40 treated by hemodialysis via AV fistula(HD group) in Baghdad teaching hospital from April 2015 to April 2016 several patients were excluded initially from study due to long term multiple comorbidities and long history of COPD, HF, & valvular heart disease. This study take approval of ethical committee from Arab board department of medicine in Iraq. Informed patient consent according to Helsinki declaration were taken, also all patients selected in our study perform pulmonary function test to exclude respiratory problem and avoid false positive results and all them show accepted results that indicate proper selection of groups.

Patient evaluation: Systolic PASP was estimated in 80 patients by Doppler echocardiography. All patients in 2nd group (HD group) had a duration ranging from 3 to 6 months on HD which was sufficient time for pathophysiological changes to occur. To avoid overestimation of PAP due to volume overload, the echocardiography performed within few hours (between 2 to 5 hours) post session of HD while patient in dry weight after estimation of blood pressure and body weight. Doppler echocardiography was obtained for each patient. PASP was calculated using modified Bernoulli equation:

\[
PASP=4(v_{tricuspid~regurgitation~jet})^2+(estimated~right~atrial~pressure).\]

Right a trial pressure measured by vena cava diameter & degree of inspiratory collapse7.

Diagnostic criteria: PH mean >25mmHg measured by right side catheterization in addition to pulmonary wedge pressure<15mmHg&pulmonary vascular resistance >3woods unit.vNoninvasive measurement of PH can be done by Doppler echocardiography. In echo study measurement of PASP based on T.V. regurgitation jet with exclusion of other physiological &pathological causes. Significant PH occur when PASP>50mmHg&/or TVR>3.4m/s, but as grades of Severity classified to mild (below 45 mmHg), moderate (46mmHg-60 mmHg), severe(more than 60 mmHg).The machine used was Philips CX50, and views were apical 4 chambers, parasternal short axis& RV inflow views. This echo study done by professional echo doctor from Baghdad teaching hospital. Echo study was done for 1st group on conservative treatment, and in dialysis unit by same machine for 2nd group on HD.

Statistical analysis: Data of all patients were entered and analyzed with the statistical package of social sciences (SPSS) version 21.Age and duration on HD were presented as mean ± standard deviation (SD), other variables were presented as frequencies (numbers) and proportions (%). Student’s test was used to compare means. Chi square test was used to compare frequencies. Odds ratio (OR) was calculated to estimate the risk and the association of PHT with each of Anemia and viral screening findings. Level of significance (P value) was set at 0.05 as cutoff point for significant difference or association. Results were presented in tables with an explanatory paragraph for each table by using Microsoft Office word software version 2010.

3. Results

There were 80 patients with CKD enrolled in this study, 40 of them (50%) were on conservative treatment (pre dialysis group) and the other 40 patients on HD (HD group). The mean age of patients in pre dialysis group was 51.6 ± 14.2 years compared to 53.4 ± 12.6 years in HD group, with a range of 20 – 70 years (table 1).

![Table 1](image-url)

<table>
<thead>
<tr>
<th>Variable</th>
<th>Pre dialysis group</th>
<th>HD Group</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td>51.6 ± 14.2</td>
<td>53.4 ± 12.6</td>
<td>0.34</td>
</tr>
<tr>
<td>Range</td>
<td>20 – 70</td>
<td>20 – 70</td>
<td></td>
</tr>
<tr>
<td>Duration on HD (months)</td>
<td>-</td>
<td>4.1 ± 1.3</td>
<td>-</td>
</tr>
<tr>
<td>Range</td>
<td>-</td>
<td>3 – 6</td>
<td>-</td>
</tr>
</tbody>
</table>

DM was found in 13 patients (32.5%) of pre dialysis group and 12 patients (30%) in HD group and was of no statistical significance. Anemia was significantly more frequent in HD group than predialysis group, it was found in 11 pre dialysis patients (27.5%) and 22 (55%) of HD patients (P=0.021). Hypertension reported in 10 predialysis patients (25%) and 13 (32.5%) of HD patients and was found of no statistical significance, other diseases were found to be less frequent distribution, no significant differences had been found in between studied groups regarding the hypertension, Chronic infection, stones, systemic lupus erythematosus (SLE) or polycystic kidney disease (PKCD), in all comparison at P>0.05. Regarding PHT it was reported in 5 pre dialysis patients giving a prevalence of 12.5% among this group, and it was found in 12 HD patients with a prevalence of 30%, it had been significantly found PHT was more prevalent in patients on HD than predialysis patients. Patients on HD were about 3 folds more likely to have PH (odds ratio = 3, P=0.02) (table 2).
It had been found that there is correlation between pulmonary hypertension and Total anemia and also was more prevalent in anemic patients. Anemic patients were About 3.4 folds more likely to have PH, OR=3.42, P= 0.026 (table 3).

<table>
<thead>
<tr>
<th>Variable</th>
<th>Pre dialysis Group</th>
<th>HD Group</th>
<th>OR *</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>No.</td>
<td>%</td>
<td>No.</td>
</tr>
<tr>
<td>Pulmonary hypertension</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Present</td>
<td>5</td>
<td>12.5</td>
<td>12</td>
</tr>
<tr>
<td>Absent</td>
<td>35</td>
<td>87.5</td>
<td>28</td>
</tr>
<tr>
<td>Severity of PHT</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mild&lt; 45 mmHg</td>
<td>1</td>
<td>20.0</td>
<td>1</td>
</tr>
<tr>
<td>Moderate 45 – 60 mmHg</td>
<td>3</td>
<td>60.0</td>
<td>9</td>
</tr>
<tr>
<td>Severe &gt; 60 mmHg</td>
<td>1</td>
<td>20.0</td>
<td>2</td>
</tr>
<tr>
<td>OR= odds ratio</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Table 2: Distribution of PHT among studied groups

PH is prevalent in patients with CKD that indicating it contributes in pathogenesis of PH, and there is significant increase in prevalence in patients with ESRD on HD. Several risk factors including LV dysfunction, AV Fistula, anemia &imbalance between vasoconstrictor & vasodilator substances are implicated in PH in patients with CKD. PH has been associated with a higher risk of death in patient with CKD.

5. Conclusion

The authors acknowledge the contribution and cooperation of the patients enrolled for the study.

6. Acknowledgments

No funding sources.

8. Conflict of interest

None declared.
References


Author Profile

Dr. ALI A. Allawi FRCP (London), Assistant professor Baghdad College of medicine university of Baghdad. Consultant in nephrology and kidney transplantation at the Medical City Teaching Hospital Complex, The Iraqi Center for kidney diseases and Transplant Center. Qualified with M.B.Ch.B at 1990 from College of Medicine, University of Baghdad. F.I.C.M. in Medicine (fellow of Iraqi committee of medical Specialization) since 1999. F.I.C.M. in Nephrology (Iraqi Board of Medical Specialization) since 2003. A member of kidney transplant teams at The Iraqi Center for kidney diseases and transplantation and Jenin Private Hospital. A Director of Consultants committee of nephrology and renal transplantation at The Ministry of Health since 2012 and current. Supervisor and Examiner / Arabic and Iraqi Boards of Nephrology and Internal Medicine. Several researches in nephrology and internal medicine was published. A member of the following Professional societies: (ASN) AMERICAN Society of Nephrology International Society of Nephrology (ISN ) European Renal Association -European Dialysis &Transplant Association (ERA-EDTA), The Transplantation Society TTS Arab Society of Nephrology and Renal Transplant (ASNRT) member of Iraqi Society of Nephrology